On December 11, 2023, Sanofi launched a assertion that it’s going to terminate its proposed $755 million licensing settlement with Maze Therapeutics (Maze) shortly after the Federal Commerce Fee (FTC) issued an administrative grievance and approved submitting a grievance for preliminary injunction in the US District Court docket for the District of Massachusetts to dam the deal.
Below the phrases of the proposed licensing settlement between Genzyme Company, a wholly-owned subsidiary of Sanofi, and Maze, Sanofi would purchase an unique license to Maze’s glycogen synthase 1 merchandise and associated expertise, together with its candidate MZE001, a drug in growth to deal with the doubtless deadly genetic order Pompe illness. In keeping with an announcement by Jason Coloma, Ph.D., Maze’s CEO, the FTC’s problem “is the primary time ever the FTC has moved to dam a license of a Section 1 investigational medication.” The problem appears constant, nonetheless, with revised draft merger pointers proposed by the FTC and Division of Justice that point out that transactions “mustn’t entrench or prolong a dominant place” by, for instance, “[e]liminating a nascent aggressive risk.”
The grievance alleges that Sanofi has been the dominant provider of medicine that deal with Pompe illness for over a decade and that the deal would eradicate competitors from MZE001, a glycogen synthase 1 inhibitor in growth at Maze that might compete with Sanofi’s medication used to deal with Pompe illness. The grievance raises two counts—one for alleged monopolization and unfair methodology of competitors underneath Part 2 of the Sherman Act and Part 5 of the FTC Act; and one for unlawful acquisition and unfair methodology of competitors underneath Part 7 of the Clayton and Part 5 of the FTC Act. In contrast to another latest enforcement actions by the FTC, there isn’t a standalone violation of Part 5 of the FTC Act alleged.
No Comments
Leave a comment Cancel